GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Institutional Ownership

NextCell Pharma AB (OSTO:NXTCL) Institutional Ownership : 0.01% (As of Jun. 19, 2024)


View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NextCell Pharma AB's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NextCell Pharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NextCell Pharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.


NextCell Pharma AB Institutional Ownership Historical Data

The historical data trend for NextCell Pharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Institutional Ownership Chart

NextCell Pharma AB Historical Data

The historical data trend for NextCell Pharma AB can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

NextCell Pharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


NextCell Pharma AB (OSTO:NXTCL) Business Description

Traded in Other Exchanges
Address
Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB (OSTO:NXTCL) Headlines

No Headlines